Clinical trials: Paget Disease
Osseous Paget's Disease
Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -
The purpose of this study is to evaluate the safety and efficacy of sodium risedronate tablets administered once daily (one tablet per dose) in patients with osseous Paget's disease for 48 weeks from baseline in daily medical…
- Trial name
- NCT02106455
- Testing
- Sodium risedronate
- Where
- 2 sites in Japan
- Volunteers
- 315 people
- Sponsor
- Takeda
Paget's Disease of Bone
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
The primary objective of this core study was to show non-inferiority of zoledronic acid to risedronate, with respect to the proportion of patients who achieved therapeutic response.
- Trial name
- NCT00103740
- Testing
- zoledronic acid, Risedronate, Calcium and vitamin D supplements
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of the Bone
Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and…
- Trial name
- NCT00740129
- Testing
- Zoledronic Acid
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Metastatic Breast Cancer
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
This was a national, multi-center, open-label, phase IIIb trial to determine the efficacy and safety of treatment with ribociclib (LEE011) plus letrozole in patients with HR+, HER2-negative advanced (recurrent or metastatic)…
- Trial name
- NCT03096847
- Testing
- ribociclib, letrozole, goserelin
- Where
- 84 sites in Germany
- Volunteers
- 502 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of the Bone, Hypocalcemia
Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
This study will evaluate the impact of investigator and patient education and educational materials to foster calcium and vitamin D supplementation to mitigate the potential for hypocalcemia post Reclast® administration in…
- Trial name
- NCT00668200
- Testing
- Reclast (ZOL446, zoledronic acid), Calcium, Vitamin D
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of Bone
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
The core study looked at the effect of Zoledronic Acid given once as an intravenous (i.v.) infusion compared to 60 days of oral Risedronate in patients with Paget's disease of bone.
- Trial name
- NCT00051636
- Testing
- Zoledronic Acid, Risedronate, Calcium and Vitamin D
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of Bone
A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)
To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.
- Trial name
- NCT00480662
- Testing
- alendronate
- Volunteers
- 60 people
- Sponsor
- Organon and Co
Neoplasms, Breast
Lapatinib and Bevacizumab for Metastatic Breast Cancer
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
- Trial name
- NCT00444535
- Testing
- lapatinib, bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of Bone
Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)
The purpose of this study is to document the efficacy and safety profiles of single intravenous dose of 5 mg zoledronic acid for the Chinese patients of Paget's Disease of Bone (PDB).
- Trial name
- NCT00774020
- Testing
- Zoledronic acid
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Parkinson Disease
Data Collection Study for the Spectrum Dynamics Multi-purpose CZT SPECT Camera
This study evaluates SPECT image data acquired from Spectrum Dynamics' multi-purpose CZT SPECT-CT camera. All subjects will undergo routine clinical Anger SPECT imaging and an additional SPECT acquisition on the CZT SPECT camera.
- Conditions
- Dementia, Parkinson Disease, Pulmonary Hypertension, Heart Diseases
- Trial name
- NCT03438123
- Testing
- CZT SPECT imaging
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Spectrum Dynamics
Neoplasms, Breast
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
This is a randomised, open label multicenter Phase III study comparing the efficacy of neoadjuvant lapatinib plus paclitaxel, versus trastuzumab plus paclitaxel, versus concomitant lapatinib and trastuzumab plus paclitaxel given…
- Trial name
- Neo ALTTO (NCT00553358)
- Testing
- Lapatinib, Trastuzumab, Paclitaxel
- Where
- 121 sites in Argentina, Belgium and 22 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals